Literature DB >> 16957428

Blood pressure components in clinical hypertension.

Michel E Safar1, Harold Smulyan.   

Abstract

This review offers a critical evaluation of the remarkable progress in antihypertensive therapy since its inception. Despite the introduction of newer, more sophisticated drugs, treatment results have remained stable. Problems impeding further improvement include limited patient compliance, clinical inertia, incomplete adherence to guidelines, and dependence on brachial artery cuff pressures for diagnosis, risk assessment, and treatment response. Brachial artery systolic and pulse pressures do not reliably represent aortic or carotid artery pressures, which are better risk predictors for the heart and brain. Mean pressure, which is the same throughout the arterial tree, is directly measurable by cuff oscillometry, and might become the best single risk predictor. Available drugs have limited ability to decrease the aortic stiffness that is responsible for the elevated systolic blood pressure of aging. Therefore, to improve risk assessment and therapeutic benefit, we might include mean blood pressure and pulse pressure into blood pressure measurements, pursue efforts to measure central blood pressure, and search for new drugs to reduce arterial stiffness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16957428      PMCID: PMC8109579          DOI: 10.1111/j.1524-6175.2006.05351.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  33 in total

1.  The paradigm has shifted, to systolic blood pressure.

Authors:  H R Black
Journal:  Hypertension       Date:  1999-09       Impact factor: 10.190

2.  What does STOP-2 tell us about management of hypertension?

Authors:  M E Safar; J Blacher; J J Mourad; G London; E D Frohlich
Journal:  Lancet       Date:  2000-02-19       Impact factor: 79.321

Review 3.  Hypertensive therapy: Part II.

Authors:  Veronica Franco; Suzanne Oparil; Oscar A Carretero
Journal:  Circulation       Date:  2004-06-29       Impact factor: 29.690

Review 4.  Epidemiology of uncontrolled hypertension in the United States.

Authors:  Thomas J Wang; Ramachandran S Vasan
Journal:  Circulation       Date:  2005-09-13       Impact factor: 29.690

5.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

6.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

7.  Detection and treatment of hypertension at the work site.

Authors:  M H Alderman; E E Schoenbaum
Journal:  N Engl J Med       Date:  1975-07-10       Impact factor: 91.245

Review 8.  Oscillometric blood pressure measurement: progress and problems.

Authors:  G A van Montfrans
Journal:  Blood Press Monit       Date:  2001-12       Impact factor: 1.444

9.  Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population.

Authors:  Athanase Benetos; Frédérique Thomas; Kathryn E Bean; Louis Guize
Journal:  J Hypertens       Date:  2003-09       Impact factor: 4.844

10.  Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.

Authors:  S MacMahon; R Peto; J Cutler; R Collins; P Sorlie; J Neaton; R Abbott; J Godwin; A Dyer; J Stamler
Journal:  Lancet       Date:  1990-03-31       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.